Apexian Pharmaceuticals
Manufacturing · Indiana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 N Meridian St Ste 801, Indianapolis, ...Phone Number
(317) 684-9196Website
www.apexianpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Apexian Pharmaceuticals
Apexian Pharmaceuticals, Inc. is focused on developing novel compounds to treat cancer and other life-threatening diseases mediated by the APE1/Ref-1 protein. Their lead drug candidate, APX3330, targets this protein, which is implicated in various cancers and inflammation-related conditions. The company aims to provide safe and effective therapies for patients suffering from high unmet medical needs, including cancers of the colon, pancreas, and skin, as well as diabetic macular edema and inflammatory bowel disorders. Apexian's experienced team is advancing their clinical programs, having completed a phase 1 study and preparing for further development of APX3330.Explore more
Apexian Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apexian Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Apexian Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Apexian Pharmaceuticals launches new products
Check out if Apexian Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Apexian Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Apexian Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Apexian Pharmaceuticals has new funding data
Earning: See what the market has to say on Apexian Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Apexian Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Apexian Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Apexian Pharmaceuticals
Compare insights from companies similar to Apexian Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apexian Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Apexian Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Apexian Pharmaceuticals.
Apexian Pharmaceuticals financials insights
Gather financial insights about Apexian Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Private Equity
$2.5M
2015
Debt
$750K
2016
Private Equity
$1.3M
Apexian Pharmaceuticals Tech Stack
A closer look at the technologies used by Apexian Pharmaceuticals
Apexian Pharmaceuticals News & Media
APX3330 Phase I Oncology Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Apexian Pharmaceuticals, Inc., a clinical-stage drug development company focused on advancing APX3330 for the treatment of diseases mediated by t ...Apexian Pharmaceuticals' Clinical Candidate, APX3330, to Be Studied in Diabetic Models of Preleukemic Cells With Specific Mutations to Leukemia
INDIANAPOLIS, July 2, 2019 /PRNewswire/ -- Apexan Pharmaceuticals, Inc. is pleased to announce that The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has awarded a $2.3 million grant to Dr. Reuben Kapur and Dr. Mark R. Kelley, investigators in the...APX3330 Phase 1 Oncology Trial Selected for ASCO Poster Presentations on June 1, 2019
INDIANAPOLIS, May 31, 2019 /PRNewswire/ -- Apexian Pharmaceuticals, Inc., a clinical stage drug development company focused on advancing APX3330 for the treatment of diseases mediated by the APE1/Ref-1 protein, today announced that it will report clinical data from its clinical study,...Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia
INDIANAPOLIS--(BUSINESS WIRE)--An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia. Apexian Pharmaceuticals’ latest studies in collaboration with Indiana University’s Simon Cancer Center investigator Dr. Reuben Kapur show promise for halting that transformation. These results, published December 6, 2018, in Cell Stem Cell, explain how a long noncoding RNA called Morrbid becomes hyperacti
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Apexian Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Apexian Pharmaceuticals, Inc. is focused on developing novel compounds to treat cancer and other life-threatening diseases mediated by the APE1/Ref-1 protein. Their lead drug candidate, APX3330, targets this protein, which is implicated in various cancers and inflammation-related conditions. The company aims to provide safe and effective therapies... Read More
